Dehghanbanadaki Hojat, Aazami Hossein, Ejtahed Hanieh Sadat, Sohrabi Ahmad, Raftar Shahrbanoo Keshavarz Azizi, Tarashi Samira, Tabatabaei-Malazy Ozra, Bahramali Golnaz, Siadat Seyed Davar, Esfahani Ensieh Nasli, Razi Farideh
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord. 2021 Nov 18;21(1):13-32. doi: 10.1007/s40200-021-00920-1. eCollection 2022 Jun.
Modifying gut dysbiosis has achieved great success in managing type 2 diabetes mellitus (T2DM) and also T2DM affected the gut microbial composition.
To determine the research trend of scientific publications on the relationship between gut microbiota and T2DM through a bibliometric and descriptive approach.
We included originals and reviews related to both topics of gut microbiota and T2DM through searching in Scopus up to 31 December 2019 and then characterized their bibliometric profiles including the number of publications, citations, institutions, journals, countries, and the collaboration network of authors, countries, terms and keywords. Moreover, we performed a descriptive evaluation of the clinical trials based on their intervention type and its influence on gut dysbiosis.
We achieved 877 articles (436 originals and 441 reviews) according to our inclusion criteria. The annual publications were constantly increased over time and reached 220 publications in 2019. Out of 436 original articles, 231 animal studies and 174 human studies were found. The majority of human studies were clinical trials ( = 77) investigating the influence of drugs ( = 21), regimens ( = 21), pre/pro/symbiotic ( = 19), surgeries ( = 15), or both drug and regimen ( = 1) on gut dysbiosis. Roux-en-Y gastric bypass and metformin were assessed the most in these trials. Obesity side by side T2DM has been assessed in this area of literature based on term and keyword analyses showing their possible similar pathways mediated by gut microbiota.
The exponentially growing documents on gut microbiota and T2DM had been published during the last decade and revealed gut microbiota alteration mediated antidiabetic effect of many interventions. Thus, we suggest other researchers to consider this pathway in efficacy assessment of therapeutic modalities and to find the optimal composition of gut microbiota that guarantees healthy insulin sensitivity.
The online version contains supplementary material available at 10.1007/s40200-021-00920-1.
调节肠道菌群失调在2型糖尿病（T2DM）的管理方面已取得巨大成功，并且T2DM也会影响肠道微生物组成。
通过文献计量学和描述性方法确定关于肠道微生物群与T2DM之间关系的科学出版物的研究趋势。
我们通过在Scopus中检索截至2019年12月31日的与肠道微生物群和T2DM这两个主题相关的原创文章和综述，然后对其文献计量学特征进行描述，包括出版物数量、引用次数、机构、期刊、国家以及作者、国家、术语和关键词的合作网络。此外，我们根据临床试验的干预类型及其对肠道菌群失调的影响进行了描述性评估。
根据我们的纳入标准，共获得877篇文章（436篇原创文章和441篇综述）。年度出版物数量随时间不断增加，2019年达到220篇。在436篇原创文章中，发现231篇动物研究和174篇人体研究。大多数人体研究是临床试验（n = 77），调查药物（n = 21）、治疗方案（n = 21）、益生元/益生菌/合生元（n = 19）、手术（n = 15）或药物与治疗方案两者（n = 1）对肠道菌群失调的影响。在这些试验中，Roux-en-Y胃旁路手术和二甲双胍的评估最多。基于术语和关键词分析，在该文献领域中已对肥胖与T2DM进行了评估，显示它们可能通过肠道微生物群介导相似的途径。
在过去十年中，关于肠道微生物群和T2DM的文献呈指数级增长，揭示了许多干预措施通过肠道微生物群改变介导的抗糖尿病作用。因此，我们建议其他研究人员在治疗方式的疗效评估中考虑这一途径，并找到能保证健康胰岛素敏感性的最佳肠道微生物群组成。
在线版本包含可在10.1007/s40200-021-00920-1获取的补充材料。
